Evidence map›Paper›PMID 36175145›Full record

ArticleNeurology2023

Incidence of Status Migrainosus in Olmsted County, Minnesota, United States: Characterization and Predictors of Recurrence.

Juliana H VanderPluym, Kartik Mangipudi, Amir Abdallah Mbonde, David Gritsch, Edoardo Caronna, Rashmi B Halker Singh, Richard J Butterfield, Jonathan H Smith

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Juliana H VanderPluymFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain. vanderpluym.juliana@mayo.edu.
Kartik MangipudiFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Amir Abdallah MbondeFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
David GritschFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Edoardo CaronnaFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Rashmi B Halker SinghFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Richard J ButterfieldFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jonathan H SmithFrom the Departments of Neurology (J.H.V., K.M., A.A.M., D.G., R.B.H.S., J.H.S.) and Quantitative Health Sciences (R.J.B.), Mayo Clinic, Scottsdale, AZ; and Neurology Department (E.C.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Vall d'Hebron Hospital Universitari · ES

Funding

Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

BACKGROUND AND

objectivesSM is recognized as a complication of migraine in which pain and/or associated symptoms are unremitting and debilitating for more than 72 hours. The epidemiology of SM in the general population is not known. The aim of this study is to determine the incidence, recurrence rate, and clinical associations of status migrainosus (SM) in care-seeking residents of Olmsted County, Minnesota.

methodsThe Rochester Epidemiology Project was used to identify the incident cases of SM according to the

resultsBetween January 1, 2012, and December 31, 2017, 237 incident cases of SM were identified. The median age was 35 (IQR 26-47) years, and 210 (88.6%) were female. A history of chronic migraine was recorded in 82/226 (36.3%) and a history of aura in 76/213 (35.7%). At the time of the incident case, medication reconciliation included a triptan or ergotamine in 127/233 (53.6%) and/or an opioid-containing analgesic in 43/233 (18.5%). The overall age- and sex-adjusted incidence rate was 26.60 per 100,000 [95% CI, 23.21-29.97], with a peak incidence between ages 40 and 49 years. The median (95% CI) attack duration was 5 (4.48-5.42) days. The most frequent triggers were stress (40/237, 16.9%) and too much or too little sleep (27/237, 11.4%). Recurrence occurred in 35/237 (14.8%) at a median of 58 (IQR 23-130) days following the initial attack. In our age- and sex-adjusted multivariable model, too much or too little sleep as a trigger was associated with 12-month risk of recurrence (adjusted OR 3.59 [95% CI 1.58-8.14], DISCUSSION: Our study provides a population-based estimate of SM incidence. We identified aberrant sleep patterns as a potentially modifiable risk factor for 1-year SM recurrence.

Indexed as

Migraine DisordersAdultAnalgesics, OpioidFemaleHeadacheHumansIncidenceMaleMiddle AgedMinnesotaSleepUnited StatesAnalgesics, Opioid

Identifiers

PMID36175145
PMCPMC10615570
OpenAlexW4297989753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.